drugset / Trial / NCT06506305
Clinical Study of FB1001 in Patients
Phase 1
Not yet recruiting
59 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
4B Technologies Limited · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single/multiple intravitreal injection of FB1001 in patients with APACG(Acute Primary Angle-Closure Glaucoma) or NAION(Nonarteritic Anterior Ischemic Optic Neuropathy).
Timeline
- Start
- 2024-08-15
- Primary completion
- 2026-06-30
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FB1001 | Monoclonal antibody | — | Intravitreal |